Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH; Korean Multiple Myeloma Working Party.
Lee SS, et al. Among authors: kim bs, kim hy, kim k.
Ann Hematol. 2010 Sep;89(9):905-12. doi: 10.1007/s00277-010-0943-z. Epub 2010 Mar 27.
Ann Hematol. 2010.
PMID: 20349060
Clinical Trial.